Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00377065
First received: September 14, 2006
Last updated: November 13, 2013
Last verified: November 2013

September 14, 2006
November 13, 2013
Not Provided
Not Provided
Not Provided
Expanded Access Program
Complete list of historical versions of study NCT00377065 on ClinicalTrials.gov Archive Site
Not Provided
Expanded Access Program
Not Provided
Not Provided
 
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options

This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.

Not Provided
Expanded Access
Not Provided
Not Provided
HIV Infections
Drug: raltegravir
raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
Other Names:
  • MK0518
  • ISENTRESS™
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Approved for marketing
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • HIV positive patients who have limited or no treatment options and have documented resistance

Exclusion Criteria:

  • Patient has previously been on MK0518 therapy
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00377065
0518-023, MK0518-023, 2006_031
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP